Cytophage Technologies Ltd.
CYTO.V
TSX
| 09/30/2024 | 06/30/2024 | 09/30/2023 | |||
|---|---|---|---|---|---|
| Net Income | 12.35% | 71.32% | 11.53% | ||
| Total Depreciation and Amortization | 2.84% | -4.16% | 2.54% | ||
| Total Amortization of Deferred Charges | -- | -- | -- | ||
| Total Other Non-Cash Items | 64.13% | -100.93% | -89.83% | ||
| Change in Net Operating Assets | -9.09% | 108.78% | -63.61% | ||
| Cash from Operations | 16.32% | 51.44% | -71.67% | ||
| Capital Expenditure | 53.16% | -1,132.03% | 47.35% | ||
| Sale of Property, Plant, and Equipment | -- | -- | -- | ||
| Cash Acquisitions | -- | -- | -- | ||
| Divestitures | -- | -- | -- | ||
| Other Investing Activities | -- | -100.00% | -- | ||
| Cash from Investing | 53.16% | -109.86% | 47.35% | ||
| Total Debt Issued | -- | -- | -- | ||
| Total Debt Repaid | 25.84% | 11.44% | -6.05% | ||
| Issuance of Common Stock | -100.00% | -99.80% | -43.13% | ||
| Repurchase of Common Stock | -- | -- | -- | ||
| Issuance of Preferred Stock | -- | -- | -- | ||
| Repurchase of Preferred Stock | -- | -- | -- | ||
| Total Dividends Paid | -- | -- | -- | ||
| Other Financing Activities | -- | 100.00% | 100.00% | ||
| Cash from Financing | 21.75% | 33.81% | -48.14% | ||
| Foreign Exchange rate Adjustments | -- | -- | -- | ||
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | ||
| Net Change in Cash | 31.59% | -134.05% | -224.87% | ||